Ozalp, Veli CengizUcak, SametDursun, Ali D.Sudagidan, MertIcin, OykuVakifahmetoglu, CekdarGurlo, AleksanderBasic Sciences2024-07-052024-07-0520231773-22472588-894310.1016/j.jddst.2023.1046222-s2.0-85161988721https://doi.org/10.1016/j.jddst.2023.104622https://hdl.handle.net/20.500.14411/2214Özalp, Veli Cengiz/0000-0002-7659-5990; Dursun, Ali Dogan/0000-0001-9056-0025; UCAK, SAMET/0000-0002-3461-2481; Gurlo, Aleksander/0000-0001-7047-666X; Vakifahmetoglu, Cekdar/0000-0003-1222-4362; ICIN ERDEMIR, OYKU/0000-0002-8228-7409; Simon, Ulla/0000-0001-6233-6595Different ordered mesoporous silica (OMS) nanoparticles, ranging from regular COK-12 to COK-12 modified in terms of pore shape and size, have been employed as standard drug carriers for the controlled adsorption and release of drug molecules in comparison to well-known OMS SBA-15 and MCM-41. The cytotoxicity analysis demonstrated that regular COK-12 particles were less harmful to mammalian cultured cells, causing lower apoptosis induction than modified COK-12, MCM-41, and SBA-15 particles.Thus, regular COK-12 was further used to prepare a dual antibiotic-loaded drug delivery material, followed by surface functionalization with Staphylococcus aureus-specific aptamers for targeting. The results demonstrated that the joint loading of lysozyme and vancomycin in regular COK-12 improved the ability of the antibiotic treatments to kill methicillin-resistant Staphylococcus strains via aptamer targeting. The minimum inhibitory concentration (MIC) values decreased 4.1-fold and 12-fold compared to the non-targeted use of the antimicrobial agents in homogeneous solutions for vancomycin and lysozyme, respectively, clearly demonstrating the high potential of COK-12 to be used as a carrier in multidrug therapy.eninfo:eu-repo/semantics/closedAccessCOK-12Ordered mesoporous silicaAntimicrobialsMethicillin-resistant Staphylococcus aureusAptamersDrug releaseArticleQ1Q186WOS:0010324869000011